Industrial Policy & Trade Monitor· 2667 actions· ✨ 89 recent

The Union Cabinet approved the Semicon India Programme on 15 December 2021, establishing the India Semiconductor Mission (ISM) as the nodal agency. The programme offers fiscal support of up to 50% of project cost for silicon semiconductor fabs, compound semiconductor facilities, display fabs, ATMP/OSAT units, and chip design. Total outlay: Rs 76,000 crore (approximately $10.2bn at 2021 exchange rates). By February 2024, the Cabinet had approved three major semiconductor units under ISM: Tata Electronics with PSMC (semiconductor fab, Dholera, Rs 91,526 crore), Tata Electronics OSAT (Morigaon, Assam, Rs 27,120 crore), and CG Power OSAT (Rs 7,584 crore), totalling over Rs 1.26 lakh crore in committed investment from private applicants.

The Union Cabinet on 12 May 2021 approved the Production-Linked Incentive (PLI) Scheme "National Programme on Advanced Chemistry Cell (ACC) Battery Storage" with a Rs 18,100 crore (~USD 2.4 bn) outlay over five years to build 50 GWh of ACC and 5 GWh of "Niche" ACC manufacturing capacity in India. Selected bidders receive PLI cash incentives over five years on sale of cells made in India, gated on minimum 25% domestic value addition rising to 60% by year five and chemistry-agnostic eligibility (Li-ion, Na-ion, solid-state, flow, lead-acid). The MHI awarded the first 50 GWh tranche on 24 March 2022 (Hyundai Global Motors 20 GWh, Ola Electric 20 GWh, Reliance New Energy Solar 5 GWh, Rajesh Exports 5 GWh) under a QCBS global tender; the Hyundai Global Motors award was withdrawn after Hyundai Motor Company disowned the bidder in August 2022, triggering a re-tender of the orphaned capacity that completed in 2025.

The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.

The Union Cabinet approved the Production Linked Incentive (PLI) Scheme for Large Scale Electronics Manufacturing on 21 March 2020, with the scheme notified in the Gazette of India on 1 April 2020. Total outlay: Rs 40,995 crore (~$5.5bn) over five years. The scheme extends incentives of 4% to 6% on incremental sales (over FY 2019-20 base year) to eligible companies manufacturing mobile phones (invoice value >= Rs 15,000) and specified electronic components including ATMP units. Approved beneficiaries include Samsung, Foxconn, Wistron, Pegatron, and Indian firms Dixon, Lava, and Bhagwati (Micromax).